β2-Glycoprotein I (β2GPI) is the main autoantigenic target of antiphospholipid syndrome, with antibodies leading to clinical manifestations. There are 2 known structural isomers of β2GPI: a J shape and a circular shape. The transition between these structures is incompletely understood, with the functional implications unknown. β2GPI is a substrate of the protease plasmin, which cleaves within the fifth domain of β2GPI, leading to altered cellular binding. Very little is currently known regarding the structure and function of this protein variant. We present the first comprehensive structural characterization of plasmin-clipped β2GPI and the associated implications for pathogenic antibody binding to this protein. To determine if cleavage of B2GPI by plasmin triggers structural change, and what this change may mean for antibody reactivity. β2GPI was purified using an adapted acid-free process from healthy control plasma and cleaved with plasmin. Cleavage was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Structural characterization was undertaken using dynamic light scattering, small-angle X-ray scattering, ion mobility mass spectrometry, and molecular dynamics simulation. Activity was tested using inhibition of β2GPI enzyme-linked immunosorbent assays with patient samples and cleaved β2GPI in the fluid phase and cellular binding by flow cytometry using human umbilical vein endothelial cells. Dynamic light scattering revealed a significantly smaller hydrodynamic radius for plasmin-clipped β2GPI (P = .0043). Small-angle X-ray scattering and molecular dynamics analysis indicated a novel S-like structure of β2GPI only present in the plasmin-clipped sample, while ion mobility mass spectrometry showed different structure distributions in plasmin-clipped compared with nonclipped β2GPI. The increased binding of autoantibodies was shown for plasmin-clipped β2GPI (P = .056), implying a greater exposure of pathogenic epitopes following cleavage. Cleavage of β2GPI by plasmin results in the production of a unique S-shaped structural conformation and higher patient antibody binding. This novel structure may increase the production of antibodies and explain the loss of binding to phospholipids described previously for plasmin-clipped β2GPI.
21 August 2025 in Journal of Structural Biology: X
Beta-2-Glycoprotein I is the main target for pathogenic antiphospholipid syndrome autoantibodies. It can adopt several conformations, including an O-shape and two more linear J- and S-shapes. The in vivo existence of the O-shape is debated, and doubt remains pertaining to the pathogenic impact of each shape. Studies have shown that APS antibodies react weakly with the O-shape and bind to the linear shapes due to the exposure of a cryptic epitope in the 1st domain. How the protein transitions from O-shape to the linear shapes remains unknown. While the main epitope is widely recognised as the R39-R43 peptide, there is evidence pointing to a discontinuous epitope across domains I and II (DI & DII). We used molecular dynamics simulations to examine the potential pathways of conformational shift from the O-shape to the open forms, and the impact of plasmin clipping on these pathways. Through these studies, starting in a theorised O-shape, we identified that peptides R39-R43, T50-N56 and R63-F67 become more exposed and have increased stability in the J- and S-shapes relative to the O-shape. These changes are likely due to a shift in DII of the T106-G109 loop, which twists to form contacts with the DI K33-Y36 loop. The R39-R43 peptide is brought closer to R63-F67 suggesting a more complex DI epitope than previously theorised. These effects were observed in the wild type and plasmin clipped model, with the effect being larger in the latter. These results are in good agreement with the increased antibody binding observed experimentally for the clipped protein. We therefore suggest that we have been able to identify the structural mechanism at the residue level which results in increased antibody binding in the J-Shape, and specifically in the clipped protein.
Despite sharing ∼ 43 % sequence identity and structurally similar individual domains, botulinum neurotoxin (BoNT) serotypes A and E have differences in their properties and domain positioning. BoNT/E has a faster onset of action than BoNT/A. This difference is proposed to be due to conformational differences between BoNT/E and the other BoNT serotypes. Where most serotypes have the light chain (LC) and binding domain (BD) on opposite sides of the translocation domain (TD), BoNT/E forms a more compact shape with direct interactions between residues of the LC and BD. To elucidate the structural basis for the different properties of BoNT/A and BoNT/E, biophysical studies including molecular dynamic (MD) simulations, circular dichroism (CD) and small-angle X-ray scattering (SAXS) were applied to BoNT/A, for comparison against previous work on BoNT/E. MD simulationsat six pH values across the toxin's activation barrier (pH ∼ 5.5), followed by one extra repeat for the pH values below 5.5, revealed a rare event at pH 5 and 5.5 where interactions between a previously identified switch region of BoNT/Aand the BD were lost.This hintedat an increased freedom of movement, thus allowing the region to change from α-helical to a β-hairpin. In good agreement with previous work, CD showed a gradual and small loss of helicity as the pH decreased below pH 5.5, stabilising at pH 4.5. Combined with the relative scarcity of structural changes observed by MD in the switch region required for activity, these results may explain the slower onset of action for BoNT/A compared to BoNT/E.